Kansas City Business Journal --If timing is everything, then Jim Laufenberg said he thinks his Lenexa-based biotech firm is sitting pretty. ImmunoGenetix Therapeutics Inc. is developing an AIDS vaccine, and CEO Laufenberg has mapped out a strategy to turn an advantageous pharmaceutical landscape into what he hopes will be a more than $100 million exit strategy within a couple of years.
